Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel “basket” study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of “tumour-agnostic” targeted therapies in rare malignancies.
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions / Roviello G.; D'Angelo A.; Sciortino M.; Mini E.; Nobili S.; De Logu F.; Massi D.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - ELETTRONICO. - 152:(2020), pp. 0-0. [10.1016/j.critrevonc.2020.103011]
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Roviello G.;D'Angelo A.;Sciortino M.;Mini E.;Nobili S.;De Logu F.;Massi D.
2020
Abstract
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel “basket” study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of “tumour-agnostic” targeted therapies in rare malignancies.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
